Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s CIO Discusses Curing Cancer with AI on DojoLIVE! Interview
POAI subsidiary Helomics exec discusses the company’s quest to fight cancer Helomics tapping into the fast growing, billion-dollar AI in drug discovery market Pittsburgh-based company has been building foundational groundwork in cancer drug response profiling for two decades Helomics harnesses rich historic tumor data with the power of AI to test living tumor tissues Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that one of its executives, Helomics CIO Mark Collins, PhD, recently appeared on DojoLIVE! (http://nnw.fm/XeQG6). Helomics, a POAI subsidiary, applies artificial intelligence to its rich data…